Testosterone deficiency, cardiac health, and older men

International Journal of Endocrinology

Volumn 2014, Issue , 2014, Pages

  Hackett, G ^a,b   Kirby, M ^b,c   Sinclair, A J ^b,d  

^a BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BEDFORDSHIRE   (United Kingdom)

^c Prostate Centre   (United Kingdom)

^d LUTON AND DUNSTABLE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TESTOSTERONE;

ABLATION THERAPY; ANDROGEN DEFICIENCY; ANGINA PECTORIS; BIOCHEMISTRY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; ERECTILE DYSFUNCTION; HEART DISEASE; HEART FAILURE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INSULIN RESISTANCE; LONG TERM CARE; MALE; MORTALITY; PROSTATE; REVIEW; RISK ASSESSMENT; THERAPY EFFECT;

EID: 84899996777     PISSN: 16878337     EISSN: 16878345     Source Type: Journal    
DOI: 10.1155/2014/143763     Document Type: Review

References (72)

1. Wang C., Nieschlag E., Swerdloff R. S., Behre H., Hellstrom W. J., Gooren L. J., Kaufman J. M., Legros J. J., Lunenfeld B., Morales A., Morley J. E., Schulman C., Thompson I. M., Weidner W., Wu F. C., Investigation, treatment, and monitoring of late-onset hypogonadism in Males, ISA, ISSAM, EAU, EAA, ASA recommendation. European Urology 2009 55 21 130
2. Wylie K., Rees M., Hackett G., Anderson R., Bouloux P.-M., Cust M., Goldmeier D., Kell P., Terry T., Trinick T., Wu F., Androgens, health and sexuality in women and men. Maturitas 2010 67 3 275 289 2-s2.0-77958106876 10.1016/j.maturitas.2010.07.011
3. Wu F. C. W., Tajar A., Beynon J. M., Pye S. R., Silman A. J., Finn J. D., O'Neill T. W., Bartfai G., Casanueva F. F., Forti G., Giwercman A., Han T. S., Kula K., Lean M. E. J., Pendleton N., Punab M., Boonen S., Vanderschueren D., Labrie F., Huhtaniemi I. T., Identification of late-onset hypogonadism in middle-aged and elderly men. The New England Journal of Medicine 2010 363 2 123 135 2-s2.0-77954414397 10.1056/NEJMoa0911101
4. Bhasin S., Cunningham G. R., Hayes F. J., Matsumoto A. M., Snyder P. J., Swerdloff R. S., Montori V. M., Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. Journal of Clinical Endocrinology & Metabolism 2006 91 6 1995 2010 2-s2.0-33744948333 10.1210/jc.2005-2847
5. Khaw K.-T., Dowsett M., Folkerd E., Bingham S., Wareham N., Luben R., Welch A., Day N., Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) prospective population study. Circulation 2007 116 23 2694 2701 2-s2.0-37349118353 10.1161/CIRCULATIONAHA.107.719005
6. Oh J.-Y., Barrett-Connor E., Wedick N. M., Wingard D. L., Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002 25 1 55 60 2-s2.0-0036357643 10.2337/diacare.25.1.55
7. Shores M. M., Matsumoto A. M., Sloan K. L., Kivlahan D. R., Low serum testosterone and mortality in male veterans. Archives of Internal Medicine 2006 166 15 1660 1665 2-s2.0-33747158767 10.1001/archinte.166.15.1660
8. Tivesten Å., Vandenput L., Labrie F., Karlsson M. K., Ljunggren Ö., Mellström D., Ohlsson C., Low serum testosterone and estradiol predict mortality in elderly men. Journal of Clinical Endocrinology & Metabolism 2009 94 7 2482 2488 2-s2.0-67650248724 10.1210/jc.2008-2650
9. Vikan T., Schirmer H., Njølstad I., Svartberg J., Endogenous sex hormones and the prospective association with cardiovascular disease and mortality in men: the Tromsø study. European Journal of Endocrinology 2009 161 3 435 442 2-s2.0-70349254624 10.1530/EJE-09-0284
10. Corona G., Monami M., Boddi V., Cameron-Smith M., Fisher A. D., de Vita G., Melani C., Balzi D., Sforza A., Forti G., Mannucci E., Maggi M., Low testosterone is associated with an increased risk of MACE lethality in subjects with erectile dysfunction. Journal of Sexual Medicine 2010 7 4 1557 1564 2-s2.0-77953580935 10.1111/j.1743-6109.2009.01690.x
11. Maggio M., Lauretani F., Ceda G. P., Bandinelli S., Ling S. M., Metter E. J., Artoni A., Carassale L., Cazzato A., Ceresini G., Guralnik J. M., Basaria S., Valenti G., Ferrucci L., Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the chianti area (InCHIANTI) study. Archives of Internal Medicine 2007 167 20 2249 2254 2-s2.0-36148989115 10.1001/archinte.167.20.2249
12. Hyde Z., Norman P. E., Flicker L., Hankey G. J., Almeida O. P., McCaul K. A., Chubb S. A. P., Yeap B. B., Low free testosterone predicts mortality from cardiovascular disease but not other causes: the health in men study. Journal of Clinical Endocrinology & Metabolism 2012 97 1 179 189 2-s2.0-84855509183 10.1210/jc.2011-1617
13. Yeap B. B., Hyde Z., Almeida O. P., Norman P. E., Chubb S. A. P., Jamrozik K., Flicker L., Hankey G. J., Lower testosterone levels predict incident stroke and transient ischemic attack in older men. Journal of Clinical Endocrinology & Metabolism 2009 94 7 2353 2359 2-s2.0-67650233470 10.1210/jc.2008-2416
14. Araujo A. B., Dixon J. M., Suarez E. A., Murad M. H., Guey L. T., Wittert G. A., Endogenous testosterone and mortality in men: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism 2011 96 10 3007 3019 2-s2.0-80053558302 10.1210/jc.2011-1137
15. Haring R., Völzke H. V., Steveling A., Association of low testosterone levels with all-cause mortality by different cut-offs from recent studies. European Heart Journal 2010 31 1494 1501
16. Pye S. R., Huhtaniemi I. T., Finn J. D., Lee D. M., O'Neill T. W., Bartfai A. T., Boonen S., Casanueva F. F., Forti G., Giwercman A., Han T. S., Kula K., Lean M. E., Pendleton N., Punab M., Rutter M. K., Vanderschueren D., Wu F. C. W., Late-onset hypogonadism and mortality in aging men. The Journal of Clinical Endocrinology & Metabolism 2013 10.1210/jc.2013-2052
17. Yeap B. B., Alfonso H., Chubb S. A. P., Handelsman D. J., Hankey G. J., Almeida O. P., Golledge J., Norman P. E., Flicker L., In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. Journal of Clinical Endocrinology & Metabolism 2014 99 1 10.1210/jc.2013-3272
18. Peyman M., Oskui M. D., French W. J., Herring M. J., Guy S., Mayeda M. D., Burstein S., Kloner R. A., Testosterone and the cardiovascular system. A comprehensive review of the literature. The American Heart Association Contempory Reviews 2013 2 e000272 10.1161/JAHA.113.000272
19. Li L., Guo C. Y., Jia E. Z., Zhu T. B., Wang L. S., Cao K. J., Ma W. Z., Yang Z. J., Testosterone is negatively associated with the severity of coronary artery disease in men. Asian Journal of Andrology 2012 14 875 878
20. Malkin C. J., Pugh P. J., Morris P. D., Asif S., Jones T. H., Channer K. S., Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010 96 22 1821 1825 2-s2.0-78349305091 10.1136/hrt.2010.195412
21. Muraleedaran V., Marsh H., Kapoor D., Channer K. S., Jones T. H., Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. European Journal of Endocrinology 2013 169 6 725 733
22. Kapoor D., Aldred H., Clark S., Channer K. S., Jones T. H., Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007 30 4 911 917 2-s2.0-34147104552 10.2337/dc06-1426
23. Hackett G. I., Cole N. S., Deshpande A. A., Popple M. D., Kennedy D., Wilkinson P., Biochemical hypogonadism in men with type 2 diabetes in primary care practice. British Journal of Diabetes and Vascular Disease 2009 9 5 226 231 2-s2.0-74549224371 10.1177/1474651409342635
24. Saad F., Aversa A., Isidori A. M., Zafalon L., Zitzmann M., Gooren L., Onset of effects of testosterone treatment and time span until maximum effects are achieved. European Journal of Endocrinology 2011 165 5 675 685 2-s2.0-80054827093 10.1530/EJE-11-0221
25. Haffner S. M., Shaten J., Stern M. P., Smith G. D., Kuller L., Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. The American Journal of Epidemiology 1996 143 9 889 897 2-s2.0-0029874336
26. Traish A. M., Haider A., Doros G., Saad F., Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. International Journal of Clinical Practice 2014 68 3 314 329 10.1111/ijcp.12319
27. Kalinchenko S. Y., Tishova Y. A., Mskhalaya G. J., Gooren L. J. G., Giltay E. J., Saad F., Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clinical Endocrinology 2010 73 5 602 612 2-s2.0-78449294931 10.1111/j.1365-2265.2010. 03845.x
28. Heufelder A. E., Saad F., Bunck M. C., Gooren L., Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. Journal of Andrology 2009 30 6 726 733 2-s2.0-69949178483 10.2164/jandrol.108.007005
29. English K. M., Mandour O., Steeds R. P., Diver M. J., Jones T. H., Channer K. S., Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. European Heart Journal 2000 21 11 890 894 2-s2.0-0034108483 10.1053/euhj.1999.1873
30. Caminiti G., Volterrani M., Iellamo F., Marazzi G., Massaro R., Miceli M., Mammi C., Piepoli M., Fini M., Rosano G. M. C., Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. A double-blind, placebo-controlled, randomized study. Journal of the American College of Cardiology 2009 54 10 919 927 2-s2.0-68949172537 10.1016/j.jacc.2009.04.078
31. Svartberg J., von Mühlen D., Mathiesen E., Joakimsen O., Bønaa K. H., Stensland-Bugge E., Low testosterone levels are associated with carotid atherosclerosis in men. Journal of Internal Medicine 2006 259 6 576 582 2-s2.0-33646783661 10.1111/j.1365-2796.2006.01637.x
32. Basaria S., Coviello A. D., Travison T. G., Storer T. W., Farwell W. R., Jette A. M., Eder R., Tennstedt S., Ulloor J., Zhang A., Choong K., Lakshman K. M., Mazer N. A., Miciek R., Krasnoff J., Elmi A., Knapp P. E., Brooks B., Appleman E., Aggarwal S., Bhasin G., Hede-Brierley L., Bhatia A., Collins L., LeBrasseur N., Fiore L. D., Bhasin S., Adverse events associated with testosterone administration. The New England Journal of Medicine 2010 363 2 109 122 2-s2.0-77954421915 10.1056/NEJMoa1000485
33. Kapoor D., Aldred H., Clark S., Channer K. S., Jones T. H., Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007 30 4 911 917 2-s2.0-34147104552 10.2337/dc06-1426
34. Dobrzycki S., Serwatka W., Nadlewski S., Korecki J., Jackowski R., Paruk J., Ladny J., Hirnle T., An assessment of correlations between endogenous sex hormone levels and the extensiveness of coronary heart disease and the ejection fraction of the left ventricle in males. The Journal of Medical Investigation 2003 50 162 169
35. Rosano G., Sheiban I., Massaro R., Pgnotta P., Marazzi G., Vitale C., Mercuro G., Volterrani M., Aversa A., Fini M., Low testosterone levels are associated with coronary artery disease in male patients with angina. International Journal of Impotence Research 2007 19 176 182
36. Li L., Guo C. Y., Jia E. Z., Zhu T. B., Wang L. S., Cao K. J., Ma W. Z., Yang Z. J., Testosterone is negatively associated with the severity of coronary atherosclerosis in men. Asian Journal of Andrology 2012 14 875 878
37. Phillips G. B., Pinkernell B. H., Jing T. Y., The association of hypotestosteronemia with coronary artery disease in men. Arteriosclerosis, Thrombosis, and Vascular Biology 1994 14 701 706
38. Hackett G., Cole N., Bhartia M., Kennedy D., Raju J., Wilkinson P., Saghir A., The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice 2014 68 2 203 215
39. Mathur A., Malkin C., Saleem B., Muthusammy R., Jones C. H., Channer K., The long term benefits of testosterone on angina threshold and atheroma in men. European Journal of Endocrinology 2009 161 3 443 449
40. English K. M., Steeds R. P., Jones T. H., Diver M. J., Channer K. S., Low-dose transdermal testosterone therapy improves angina threshold in men with chromic stable angina: a randomized, double-blind, placebo-controlled study. Circulation 2000 102 16 1906 1911 2-s2.0-0034680343
41. Bai C.-X., Kurokawa J., Tamagawa M., Nakaya H., Furukawa T., Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation 2005 112 12 1701 1710 2-s2.0-25444510359 10.1161/CIRCULATIONAHA.104.523217
42. Selvin E., Feinleib M., Zhang L., Androgens and diabetes in men: results from the third National Health and Nutrition Survey (NHANES-III). Diabetes Care 2007 30 234 238
43. Stellato R. K., Feldman H. A., Hamdy O., Horton E. S., Mckinlay J. B., Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000 23 4 490 494 2-s2.0-0034106347
44. Maggio M., Basaria S., Ble A., Lauretani F., Bandinelli S., Ceda G. P., Valenti G., Ling S. M., Ferrucci L., Correlation between testosterone and the inflammatory marker soluble interleukin-6 receptor in older men. Journal of Clinical Endocrinology & Metabolism 2006 91 1 345 347 2-s2.0-30344449759 10.1210/jc.2005-1097
45. Migliaccio S., Francomano D., Bruzziches R., Trunk fat negatively influences skeletal and testicular functions in obese men: clinical implications for the aging male. International Journal of Endocrinology 2013 2013 6 182753 10.1155/2013/182753
46. Macleod J., Davey Smith G., Metcalfe C., Hart C., INTERHEART. The Lancet 2005 365 9454 118 119 2-s2.0-13744251889
47. Wang C., Swerdloff R. S., Iranmanesh R., Testosterone gel improves sexual function, mood, muscle strength and body composition in hypogonadal men. The Journal of Clinical Endocrinology & Metabolism 2000 85 8 2839 2853
48. https://www.diabetes.org.uk/Documents/Reports/State-of-the-Nation-2012. pdf
49. Jones T. H., A placebo controlled study on the effects of transdermal testosterone gel in hypogonadal men with type ii diabetes or metabolic syndrome in diabetic control and insulin sensitivity: the TIMES 2 study. Diabetes Care 2011 34 828 837
50. Kapoor D., Goodwin E., Channer K. S., Jones T. H., Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. European Journal of Endocrinology 2006 154 6 899 906 2-s2.0-33745684473 10.1530/eje.1.02166
51. Naharci M. I., Pinar M., Bolu E., Olgun A., Effect of testosterone on insulin sensitivity in men with idiopathic hypogonadotropic hypogonadism. Endocrine Practice 2007 13 6 629 635 2-s2.0-38449088185
52. Boyanov M. A., Boneva Z., Christov V. G., Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003 6 1 1 7 2-s2.0-0038823605
53. Hackett G., Cole N., Bhartia M., Wilkinson P., Raju J., Saghir A., Wilkinson P., The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). International Journal of Clinical Practice 2014 68 2 203 215 10.1111/ijcp.12235
54. Hackett G., Cole N., Bhartia M., Wilkinson P., Raju J., Wilkinson P., Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. The Journal of Sexual Medicine 2013 10.1111/jsm.12404
55. Shores M., Smith N. L., Forsberg C. W., Anawalt B. D., Marsumoto AM Testosterone treatment and mortality in men with low testosterone. The Journal of Clinical Endocrinology & Metabolism 2012 97 6 10.1210/jc.2011-2591
56. Morganuv L., Denisola I., Rohzkova T., Androgen deficit and its treatment in stroke male patients with type II diabetes. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 2011 111 8, part 2 21 24
57. Vigen R., O'Donnell C. I., Baron A. E., Grunwald G. K., Maddox T. M., Bradley S. M., Barqawi A., Woning G., Wierman M. E., Plomondon M. E., Rumsfeld J. S., Ho P. M., Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. The Journal of the American Medical Association 2013 310 17 1829 1836
58. Nehra A., Jackson G., Miner M., The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clinic Proceedings 2013 8 766 778
59. Cappola A. R., Testosterone therapy and risk of cardiovascular disease in men. The Journal of the American Medical Association 2013 310 17 1805 1806
60. Xu L., Freeman G., Cowling B. J., Schooling C. M., Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Medicine 2013 11, article 108 10.1186/1741-7015-11-108
61. Calof O. M., Singh A. B., Lee M. L., Kenny A. M., Urban R. J., Tenover J. L., Bhasin S., Adverse events associated with testosterone replacement in middle-aged and older men: a meta-analysis of randomized, placebo-controlled trials. Journals of Gerontology A 2005 60 11 1451 1457 2-s2.0-29144469309
62. Parsons J. K., Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Current Bladder Dysfunction Reports 2010 5 212 218 2-s2.0-77956261394 10.1007/s11884-010-0067-2
63. Yassin D. J., El Douaihy Y., Yassin A. A., Kashanian J., Shabsigh R., Hammerer J., Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal registry study. World Journal of Urology 2013 10.1007/s00345-013-1187-z
64. Francomano D., Ilacqua A., Bruzziches R., Lenzi A., Aversa A., Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 2014 83 1 167 174 10.1016/j.urology.2013.08.019
65. Eardley I., Optimisation of PDE5 inhibitor therapy in men with erectile dysfunction: converting "non-responders" into 'responders'. European Urology 2006 50 1 31 33 2-s2.0-33744922617 10.1016/j.eururo.2005.12.005
66. Marks L. S., Mazer N. A., Mostaghel E., Hess D. L., Dorey F. J., Epstein J. I., Veltri R. W., Makarov D. V., Partin A. W., Bostwick D. G., Macairan M. L., Nelson P. S., Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. Journal of the American Medical Association 2006 296 19 2351 2361 2-s2.0-33750978404 10.1001/jama.296.19.2351
67. García-Cruz E., Piqueras M., Ribal M. J., Huguet J., Serapiao R., Peri L., Izquierdo L., Alcaraz A., Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia. BJU International 2012 110 6, part B E199 E202 2-s2.0-84855897920 10.1111/j.1464-410X.2011.10876.x
68. Keating N. L., O'Malley A. J., Freedland S. J., Smith M. R., Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. Journal of the National Cancer Institute 2010 102 1 39 46 2-s2.0-74049152290 10.1093/jnci/djp404
69. Hackett G., Cole N., Bhartia M., Kennedy D., Raju J., Wilkinson P., Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. The Journal of Sexual Medicine 2013 10 6 1612 1617
70. Isidori A. M., Giannetta E., Gianfrilli D., Greco E. A., Bonifacio V., Aversa A., Isidori A., Fabbri A., Lenzi A., Effects of testosterone on sexual function in men: results of a meta-analysis. Clinical Endocrinology 2005 63 4 381 394 2-s2.0-26644446120 10.1111/j.1365-2265.2005.02350.x
71. Home P., Mant J., Diaz J., Turner C., Management of type 2 diabetes: updated NICE guidance. British Medical Journal 2008 336 7656 1306 1308 2-s2.0-45249107993 10.1136/bmj.39560.442095AD
72. Hackett G., Jackson G., Kirby M., Wylie K., Evidence based medicine inevitably increase testosterone prescribing. British Medical Journal 2012 345 e6167